Experimental drug Brentuximab Vedotin (SGN-35) achieved tumor volume reductions in 94% of Relapsed or Refractory Hodgkin Lymphoma patients while 34% of them achieved complete remission, Seattle Genetics reported after completing a Pivotal Clinical Trial. The company expects to submit the...
UroToday.com - The incidence of testicular cancer (TC) and Hodgkin lymphoma (HL) has increased recently. Although improved chemotherapeutic regimens have augmented survival in men with these malignancies, they are associated with a negative impact on reproductive health, including a decrease in...